

Title (en)

BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS

Title (de)

BENZIMIDAZOLE UND ANALOGA UND IHRE VERWENDUNG ALS PROTEINKINASE-HEMMER

Title (fr)

BENZIMIDAZOLES ET ANALOGUES ET LEUR UTILISATION COMME INHIBITEURS DE PROTEINES KINASES

Publication

EP 1441725 A1 20040804 (EN)

Application

EP 02801954 A 20021024

Priority

- FR 0113868 A 20011026
- GB 0204763 W 20021024
- GB 0206893 A 20020322
- GB 0206895 A 20020322
- US 39515102 P 20020711
- US 39506002 P 20020711

Abstract (en)

[origin: WO03035065A1] The invention is directed to physiologically active compounds of the general formula Ix and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula Ix, and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

[origin: WO03035065A1] The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

IPC 1-7

A61K 31/4184; C07D 403/04; C07D 403/14; C07D 413/04; C07D 413/14; C07D 405/14; C07D 409/14; C07D 491/04; C07D 401/14; C07D 487/04; C07D 471/04; A61P 35/00

IPC 8 full level

A61K 31/4184 (2006.01); A61K 31/4188 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61P 1/04 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 7/00 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 11/02 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01); A61P 19/00 (2006.01); A61P 19/02 (2006.01); A61P 19/10 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 33/00 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 39/02 (2006.01); A61P 43/00 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 491/04 (2006.01); C07D 491/056 (2006.01); C07D 521/00 (2006.01)

CPC (source: EP)

A61P 1/04 (2017.12); A61P 3/04 (2017.12); A61P 3/10 (2017.12); A61P 7/00 (2017.12); A61P 9/00 (2017.12); A61P 9/04 (2017.12); A61P 9/10 (2017.12); A61P 11/00 (2017.12); A61P 11/02 (2017.12); A61P 11/06 (2017.12); A61P 17/00 (2017.12); A61P 17/06 (2017.12); A61P 19/00 (2017.12); A61P 19/02 (2017.12); A61P 19/10 (2017.12); A61P 21/00 (2017.12); A61P 25/00 (2017.12); A61P 25/16 (2017.12); A61P 25/18 (2017.12); A61P 25/24 (2017.12); A61P 25/28 (2017.12); A61P 27/02 (2017.12); A61P 29/00 (2017.12); A61P 31/04 (2017.12); A61P 31/12 (2017.12); A61P 33/00 (2017.12); A61P 35/00 (2017.12); A61P 37/02 (2017.12); A61P 37/06 (2017.12); A61P 37/08 (2017.12); A61P 39/02 (2017.12); A61P 43/00 (2017.12); C07D 231/12 (2013.01); C07D 233/56 (2013.01); C07D 249/08 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/04 (2013.01)

Citation (search report)

See references of WO 03035065A1

Citation (examination)

- WO 9614843 A2 19960523 - COR THERAPEUTICS INC [US]
- JONAS R ET AL: "Synthesis and biological activities of meribendan and related heterocyclic benzimidazolo-pyridazinones", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 28, no. 2, 1 January 1993 (1993-01-01), pages 129 - 140, XP023870379, ISSN: 0223-5234, [retrieved on 19930101], DOI: 10.1016/0223-5234(93)90005-Y
- SAHA N ET AL: "DESIGN, SYNTHESIS AND SPECTROSCOPIC CHARACTERIZATION OF PALLADIUM(II) AND PLATINUM(II) COMPLEXES OF PYRAZOLE-DERIVED LIGANDS WITH POTENTIAL ANTI-TUMOUR PROPERTIES IN ITS HISTORICAL PERSPECTIVE", POLYHEDRON, PERGAMON PRESS, OXFORD, GB, vol. 13, no. 13, 1 January 1994 (1994-01-01), pages 2025 - 2033, XP001562249, ISSN: 0277-5387
- BAITALIK S ET AL: "Synthesis, structure, redox activity and spectroscopic properties of ruthenium(II) complexes with 3,5-bis(benzothiazol-2-yl)pyrazole, 3,5-bis(benzimidazol-2-yl)pyrazole and 2,2'-bipyridine as co-ligands", JOURNAL OF THE CHEMICAL SOCIETY, DALTON TRANSACTIONS, CHEMICAL SOCIETY, LETCHWORTH, GB, 1 January 1999 (1999-01-01), pages 719 - 727, XP001562250, ISSN: 1472-7773

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03035065 A1 20030501; AU 2002334217 B2 20080703; BR 0213562 A 20040831; CA 2465247 A1 20030501; CA 2465247 C 20100518; EP 1441725 A1 20040804; IL 161576 A0 20040927; JP 2005509633 A 20050414; JP 5039268 B2 20121003; MX PA04003954 A 20041129; UY 27516 A1 20030430

DOCDB simple family (application)

GB 0204763 W 20021024; AU 2002334217 A 20021024; BR 0213562 A 20021024; CA 2465247 A 20021024; EP 02801954 A 20021024; IL 16157602 A 20021024; JP 2003537632 A 20021024; MX PA04003954 A 20021024; UY 27516 A 20021025